There are 608 papers on LDL-C in aging research: 121 trials and 291 observational studies in people, 20 in animals, 1 in cells, 151 reviews.
608 papers study it1,628 more mention it345 findings
442 new papers in 30 daysSee all 2,236 papers on LDL-C
“Only 5mg once-weekly tirzepatide (P < 0.05), not 10 or 15 mg, could induce significant alteration in LDL-C before sensitivity analysis.”
- Human trial121
- Humans291
- Animals20
- Cells1
- In silico12
Interventions
127Inclisiran
downin humans18downin reviews2no changein humans1−56% to −48%
20 studies
Inclisiran
downin humans18downin reviews2no changein humans1−56% to −48%
Inclisiran decreases LDL-C in humans (added to statin therapy) (51% reduction (4.8 to 2.3 mmol/L)).
“Inclisiran plus statin therapy resulted in a mean LDL-C reduction of 51% (baseline 4.8 ± 0.5 → 2.3 ± 0.4 mmol/L, p<0.001)”
Human trialadded to statin therapy300 mg subcutaneously at baseline, 3 months, then every 6 months24 monthsn = 172
ESC Congress 2026 abstract
Inclisiran decreases LDL-C in humans (versus bempedoic acid at Day 150) (least squares mean -56.3% vs -15.4%; between-group difference -41.0%).
“LDL-C reduction at Day 150 was superior with inclisiran vs BPA”
Human trialversus bempedoic acid at Day 150Day 150
European heart journal
Inclisiran decreases LDL-C in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-47.50%).
“inclisiran significantly reduced LDL-C vs placebo on Day 150 (least squares mean [LSM] difference: -47.50%; P < 0.0001)”
Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207
Journal of clinical lipidology
Inclisiran decreases LDL-C in humans (chronic kidney disease stage V) (< 55 mg/dL).
“After 3 and 12 months, he attained the LDL–C target of ‹ 55 mg/dL.”
Human trialchronic kidney disease stage V284 mg s.c.12 monthsn = 1
INCLISIRAN IN TWO VERY–HIGH CV RISK PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE
European Heart Journal Supplements
Inclisiran decreases LDL-C in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-65% (to 1.3 [1.2; 2.9] mmol/L, p<0.01)).
“Ninety days post-initiation of inclisiran, LDL-C was reduced by 65% (to 1.3 [1.2; 2.9] mmol/L, p<0.01)”
Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22
Kardiologiia
Inclisiran decreases LDL-C in humans (WMD –48.99%, 95% CI –54.29 to –43.69).
“Inclisiran significantly reduced: LDL-C (WMD –48.99%, 95% CI: –54.29 to –43.69)”
Human trial
AHA Scientific Sessions 2025 abstract
Inclisiran decreases LDL-C in humans (−50.4% vs 0.2%, P<0.001).
“LDLleast C least squares mean percentage change from baseline at Day 90 was significantly greater with inclisiran + usual care vs usual care (LLT: −50.4% vs 0.2%; no LLT: −46.2% vs 5.5%; both P<0.001)”
Human trialwith usual care in participants with recent acute coronary syndrome receiving index lipid-lowering therapy300 mg (284 mg inclisiran equivalent) on Days 0, 90, and 270Day 90
AHA Scientific Sessions 2025 abstract
Inclisiran is linked with lower LDL-C in humans (-46% (95% CI -60.8 to -33.8%)).
“Median (95% CI) LDL-C reduction from baseline to nadir was - 46% (- 60.8 to - 33.8%).”
Humansup to 3 yearsn = 109
Clinical research in cardiology : official journal of the German Cardiac Society
Inclisiran is linked with lower LDL-C in humans after six administrations over two years (72.5% reduction from baseline (3.02 to 0.83 mmol/L)).
“After two years (six drug administrations), LDL-C was reduced to 0,83 mmol/L, corresponding to a 72,5% reduction from baseline”
Humansafter six administrations over two yearssix administrationstwo yearsn = 1
Russian Journal of Cardiology
Inclisiran is linked with lower LDL-C in humans (real-world cohort at a tertiary lipid service) (mean reduction 48.4% after first dose).
“Inclisiran therapy resulted in a mean LDL-C reduction of 48.4% following the first dose, sustained over 27 months.”
Humansreal-world cohort at a tertiary lipid servicefirst dose27 monthsn = 238
Real-world efficacy of inclisiran: data from a tertiary lipid clinic
The British journal of cardiology
All 21Fewer
Statins
downin humans8downin reviews1−45%
9 studies
Statins
downin humans8downin reviews1−45%
Statins are linked with lower LDL-C in humans.
“Despite a modest dose-response trend in absolute LDL-C reduction, interindividual variability was profound”
Humansone year
Atherosclerosis
Statins are linked with lower LDL-C in humans (statin therapy followed over the study period).
“A progressive improvement in lipid profile parameters was observed over the study period, with reductions in total cholesterol, LDL-C, and TG”
Humansstatin therapy followed over the study period6 months
World Journal of Current Medical and Pharmaceutical Research
Statins are linked with lower LDL-C in humans (combined with ezetimibe) (<35 mg/dL).
“LDL-C decreased to < 35 mg/dL and remained consistently suppressed.”
Humanscombined with ezetimibehigh-intensity2 yearsfemales
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
Statins are linked with lower LDL-C in multidisciplinary cardiometabolic clinic patients (-45%).
“statin (45%)”
Humansin multidisciplinary cardiometabolic clinic patients
Internal medicine journal
Statins are linked with lower LDL-C in humans (imputed underlying lipid levels in statin-treated adults) (mean 31% reduction in LDL-C (28% non-HDL-C, 26% apoB)).
“Estimated treatment effects assuming imputed underlying lipids in treated adults corresponded to mean percent reductions of 28%, 31%, and 26% for non-HDL-C, LDL-C, and apoB, respectively.”
Humansimputed underlying lipid levels in statin-treated adults
AHA Scientific Sessions 2025 abstract
Statins are linked with lower LDL-C in humans (cardiovascular disease).
“The total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and fasting blood glucose (FBG) levels were lower in the medicated group than in the nonmedicated group”
Humanscardiovascular diseasen = 2,121
Disease markers
Statins are linked with lower LDL-C in humans (104.97±36.01 vs 129.09±34.14 mg/dL).
“The mean level of LDL-C in statin use and none statin use group was 104.97±36.01 and 129.09±34.14, respectively.”
Humansn = 1,418
Journal of diabetes and metabolic disorders
Statins decrease LDL-C.
“consequently reducing low-density lipoprotein cholesterol (LDL-C) levels”
Review
Beyond LDL-C reduction: molecular pleiotropy and emerging therapeutic roles of statins
Naunyn-Schmiedeberg's archives of pharmacology
Statins decrease LDL-C in humans.
“Intensive lipid lowering remains key, with high-intensity statins, ezetimibe, and PCSK9 inhibitors used sequentially to achieve very low LDL-C targets”
Reviewhigh-intensity
Key advances in secondary prevention after coronary artery bypass grafting
Current opinion in cardiology
Bempedoic acid
downin humans8−23%
8 studies
Bempedoic acid
downin humans8−23%
Bempedoic acid decreases LDL-C in humans (−22.75%).
“The addition of BA resulted in a significant reduction in LDL-C levels, from 71.90 ± 18.03 mg/dL to 55.54 ± 14.23 mg/dL (absolute reduction: 16.36 mg/dL; relative reduction: −22.75%; p < 0.001).”
Human trialmedian follow-up duration of 28 weeks (IQR 23–47 weeks)n = 118
Journal of clinical medicine
Bempedoic acid decreases LDL-C in humans (-19% (IQR -36.4% to -3.6%, p < 0.01)).
“The median percentage change in LDL-C from baseline to week 12 was -19% (interquartile range [IQR]: -36.4% to -3.6%), decreasing from 117.5 to 92 mg/dL (p < 0.01).”
Human trial12 weeksn = 180
medRxivPreprint
Bempedoic acid decreases LDL-C in humans (hypercholesterolemia) (-24.3% (95% CI -27.8 to -20.9)).
“LDL-C fell by 24.3 % (95 % CI −27.8 to −20.9)”
Human trialhypercholesterolemia
AHA Scientific Sessions 2025 abstract
Bempedoic acid is linked with lower LDL-C in humans (mean reduction 1.05 mmol/L (SD 0.15)).
“Mean LDL-C reduction across the cohort was 1.05 mmol/L (SD 0.15)”
Humans
ESC Congress 2026 abstract
Bempedoic acid is linked with lower LDL-C in humans (-22.8% (-16.36 mg/dL)).
“BA reduced LDL-C by 22.8% (-16.36 mg/dL; p < 0.001), enabling 48.3% of patients to achieve LDL-C < 55 mg/dL.”
Humansin chronic coronary syndrome patients with LDL-C ≥ 55 mg/dL despite stable intensive lipid-lowering therapy180 mg/daymedian follow-up of 28 weeksn = 118
Journal of clinical medicine
Bempedoic acid is linked with lower LDL-C in humans (21%, p < 0.0001).
“By 3 months, BA (21%) and BA + EZE (33%, p < 0.0001 for both) were associated with significant reductions in median LDL-C levels.”
Humans3 monthsn = 900
LDL-C lowering in patients treated with bempedoic acid in a real-world cohort
Atherosclerosis plus
Bempedoic acid is linked with lower LDL-C in humans (compared with baseline LDL-C of 138 mg/dl) (88 vs 138 mg/dl baseline at 3 months; 92 mg/dl at 1 year).
“BA significantly lowered LDL-C levels at 3 months (88mg/dl +/- 32) (p <0.001)”
Humanscompared with baseline LDL-C of 138 mg/dlup to 1 year
SAT-263 Access to Bempedoic Acid - A Real World Assessment in an Academic Clinical Practice
ENDO 2025 abstract
Bempedoic acid decreases LDL-C in high- and very-high-risk individuals unable or unwilling to take statins.
“Bempedoic acid emerged as a generally safe, efficient, and cost-effective strategy to lower LDL-C and cardiovascular risk”
Reviewin high- and very-high-risk individuals unable or unwilling to take statins
Bempedoic Acid: From Guidelines to the Real World
Journal of lipid and atherosclerosis
Bempedoic acid decreases LDL-C in patients with elevated LDL-C.
“In domestic and international clinical studies, bempedoic acid reduced LDL-C levels in patients with elevated LDL-C, regardless of their response to statin therapy.”
Reviewin patients with elevated LDL-C
Nihon yakurigaku zasshi. Folia pharmacologica Japonica
PCSK9 inhibitors
downin humans8
8 studies
PCSK9 inhibitors
downin humans8
PCSK9 inhibitors decrease LDL-C in humans (compared with placebo in hypercholesterolemia) (MD –47.09%; 95% CI –53.22% to –40.96%).
“Oral PCSK9 inhibitors significantly reduced LDL-C compared to placebo (MD –47.09%; 95% CI, –53.22% to –40.96%; p < 0.001).”
Human trialcompared with placebo in hypercholesterolemiaoral
AHA Scientific Sessions 2025 abstract
PCSK9 inhibitors are linked with lower LDL-C in humans (real-world patients initiating alirocumab, evolocumab or inclisiran) (median 54.4% at 3 months and 59.2% at 6 months).
“At 3 and 6 months, LDL-C decreased by a median of 54.4% and 59.2% (both p < 0.001)”
Humansreal-world patients initiating alirocumab, evolocumab or inclisiran3 and 6 monthsn = 45
Romanian journal of internal medicine = Revue roumaine de medecine interne
PCSK9 inhibitors are linked with lower LDL-C in humans (compared with atorvastatin control group) (LDL-C reduction 25.84 vs. 21.09% (PCSK9i vs control)).
“with the PCSK9i group demonstrating greater decreases in TC (48.65 vs. 23.32%) and LDL-C (25.84 vs. 21.09%) compared to the Control group (P < 0.05)”
Humanscompared with atorvastatin control groupevolocumab injection140 mg Q2W12-week follow-upn = 60
Frontiers in medicine
PCSK9 inhibitors are linked with lower LDL-C in humans (statins plus evolocumab versus non-PCSK9i lipid-lowering regimens, over 24 weeks).
“PCSK9i group experienced significant reductions in total cholesterol (TC), triglycerides (TG), LDL-c, and an increase in HDL-c (all P<0.001)”
Humansstatins plus evolocumab versus non-PCSK9i lipid-lowering regimens, over 24 weeks140 mg biweekly24 weeksn = 184
ADA Scientific Sessions 2025 abstract
PCSK9 inhibitors decrease LDL-C in humans (High cardiovascular risk without prior myocardial infarction or stroke) (54.4% placebo-corrected reduction (95% CI 49.9 to 58.8%)).
“Pooled placebo-corrected LDL-C reduction was 54.4% (95% CI 49.9 to 58.8; I 2 =69%), consistent across populations”
ReviewHigh cardiovascular risk without prior myocardial infarction or stroken = 1,848
AHA Scientific Sessions 2026 abstract
PCSK9 inhibitors decrease LDL-C in high- and very high-risk patients.
“PCSK9 inhibitors have demonstrated significant reductions in LDL-c and decreased cardiovascular events in high- and very high-risk patients.”
Reviewin high- and very high-risk patients
New perspectives in the management of dyslipidemia and the role of PCSK9 inhibitors
Semergen
PCSK9 inhibitors decrease LDL-C in humans (early initiation in acute coronary syndrome) (substantial).
“despite substantial LDL-C reductions with early PCSK9i initiation”
Reviewearly initiation in acute coronary syndrome
BMJ open
PCSK9 inhibitors decrease LDL-C in humans (including in statin-intolerant patients).
“New lipid-lowering therapies (injectable and oral PCSK9 inhibitors, inclisiran, bempedoic acid) allow more intensive LDL-C reduction”
Reviewincluding in statin-intolerant patients
Therapeutic innovations in secondary prevention of cardiovascular risk
La Revue du praticien
Enlicitide
downin humans6−60% placebo-corrected reduction
6 studies
Enlicitide
downin humans6−60% placebo-corrected reduction
Enlicitide decreases LDL-C in humans (Placebo-corrected changes: low risk −62.6%; borderline risk −57.6%; intermediate risk −57.1%; high risk −58.0%).
“Enlicitide provided consistent LDL-C lowering across baseline PREVENT cardiovascular risk categories with corresponding reductions in apoB, Lp(a), and non-HDL-C.”
Human trialParticipants at risk for a first major ASCVD event, across baseline PREVENT cardiovascular risk categories; compared with placebo24 weeksn = 843
AHA Scientific Sessions 2026 abstract
Enlicitide decreases LDL-C in humans (placebo-corrected, Week 24, across ESC cardiovascular risk categories) (~60% LDL-C lowering in the parent trials).
“Significant placebo-corrected reductions in LDL-C, non-HDL-C, ApoB, and Lp(a) at Week 24 were demonstrated across all ESC risk categories (nominal p<0.001)”
Human trialplacebo-corrected, Week 24, across ESC cardiovascular risk categories20 mg once daily24 weeksn = 3,212
Enlicitide lowered bad cholesterol across cardiovascular risk groups
ESC Congress 2026 abstract
Enlicitide decreases LDL-C in adults with hypercholesterolemia or heterozygous familial hypercholesterolemia (MD -55.78 percentage points (95% CI -61.15 to -50.42)).
“Enlicitide achieved a substantial reduction in LDL-C (mean difference [MD]: -55.78 percentage points; 95% confidence interval [CI]: -61.15 to -50.42; p < 0.0001; I2 = 99.58%)”
Human trialin adults with hypercholesterolemia or heterozygous familial hypercholesterolemian = 3,894
Journal of cardiovascular development and disease
Enlicitide decreases LDL-C in participants with and without baseline diabetes mellitus (mean percent change -65% with diabetes and -61% without diabetes at Week 24).
“Enlicitide was associated with robust LDL-C reductions in participants with DM and without DM”
Human trialin participants with and without baseline diabetes mellitus20 mg dailyWeek 24
ADA Scientific Sessions 2026 abstract
Enlicitide decreases LDL-C in humans (hypercholesterolemia, including heterozygous familial hypercholesterolemia) (57.1% to 64.6% reduction).
“Enlicitide significantly lowered LDL-C similar to existing PCSK9is with few adverse effects.”
Reviewhypercholesterolemia, including heterozygous familial hypercholesterolemiamacrocyclic peptide formulation with permeation enhancers24 weeks
Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol
The Annals of pharmacotherapy
Enlicitide decreases LDL-C in humans (placebo-corrected, across three phase 3 trials) (~60% placebo-corrected reduction).
“achieved placebo-corrected LDL-C reductions of ~60% across three phase 3 trials”
Reviewplacebo-corrected, across three phase 3 trials
Oral PCSK9 inhibitors: closing the gap between potency and practicality
Current opinion in lipidology
Obicetrapib
downin humans6−33%
6 studies
Obicetrapib
downin humans6−33%
Obicetrapib decreases LDL-C in humans (-36.4% versus placebo).
“Monotherapy produced a -36.4% LDL-C reduction versus placebo”
Human trialPK-confirmed on-treatment patients with ASCVD or HeFH receiving maximum-tolerated lipid-lowering therapy; versus placebo84 days
Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials
ESC Congress 2026 abstract
Obicetrapib decreases LDL-C in humans (MD -37.45).
“Obicetrapib significantly reduced low-density lipoprotein cholesterol [MD, -37.45 (95% CI, -43.76 to -31.15), P < 0.001]”
Human trialn = 3,512
Cardiology in review
Obicetrapib decreases LDL-C in humans (atherosclerosis cardiovascular disease) (-33%).
“Obicetrapib significantly lowered LDL‐C by 33% and increased HDL‐C by 125% relative to placebo.”
Human trialatherosclerosis cardiovascular disease12 monthsn = 1,727
AAIC 2025 abstract
Obicetrapib decreases LDL-C in humans (on background statin therapy) (MD -37.36%; 95% CI -41.44 to -33.28).
“Obicetrapib demostrated significantly greater reductions in LDL-C (mean difference [MD]: -37.36%; 95% CI: -41.44 to -33.28; p<0.00001)”
Human trialon background statin therapy10 mg
Evaluating Lipid-Lowering Efficacy Of Obicetrapib: An Updated Meta-Analysis of Clinical Trials
AHA Scientific Sessions 2025 abstract
Obicetrapib decreases LDL-C in humans (substantial reduction).
“demonstrating substantial reductions in LDL-C, apolipoprotein B, non-HDL-C, and lipoprotein(a), alongside marked increases in HDL-C”
Review
CETP Renaissance with Obicetrapib
Current atherosclerosis reports
Obicetrapib decreases LDL-C in patients with dyslipidemia or ASCVD, pooled from RCTs (MSD -35.43 (95% CI -40.14 to -30.17)).
“It reduced LDL-C (MSD: –35.43; 95% CI: –40.14 to –30.17; I2 = 93.26%)”
Reviewin patients with dyslipidemia or ASCVD, pooled from RCTsn = 3,483
AHA Scientific Sessions 2025 abstract
Evolocumab
downin humans5−69%
5 studies
Evolocumab
downin humans5−69%
Evolocumab decreases LDL-C in addition to high-intensity statin therapy (between-group difference, −1.2 mmol/L [95% CI, −1.5 to −1.0]).
“However, evolocumab-treated patients showed greater improvement in all lipid parameters in the 12-week treatment period, including LDL-C (between-group difference, −1.2 mmol/L [95% CI, −1.5 to −1.0], i.e., −47.7 mg/dL [95% CI, −56.9 to −38.6]; p < 0.001).”
Human trialin addition to high-intensity statin therapy12 weeksn = 85
Clinical research in cardiology : official journal of the German Cardiac Society
Evolocumab decreases LDL-C in statin-naïve ACS patients undergoing PCI (31±16 mg/dL vs. 63±17 mg/dL, -77.5% vs. -53.3%).
“At 2 weeks, LDL-C levels were lower in the evolocumab group compared to the non-evolocumab group (31±16 mg/dL vs. 63±17 mg/dL; p<0.001)”
Human trialin statin-naïve ACS patients undergoing PCI140 mg2 weeksn = 108
Korean circulation journal
Evolocumab is linked with lower LDL-C in humans (add-on to statin in CHIP-NSTEACS patients) (61.3% vs. 32.2%).
“At 3 months, LDL-C reduction was 61.3% in the observation group vs. 32.2% in the control group (P < 0.001)”
Humansadd-on to statin in CHIP-NSTEACS patients3 months
Frontiers in cardiovascular medicine
Evolocumab is linked with lower LDL-C in multidisciplinary cardiometabolic clinic patients (-69%).
“Median low-density lipoprotein cholesterol level decreased with initiation of evolocumab (69%)”
Humansin multidisciplinary cardiometabolic clinic patients
Internal medicine journal
Evolocumab is linked with lower LDL-C in humans (combined with atorvastatin compared to atorvastatin alone) (P < 0.001).
“the intensive treatment group showed a more pronounced reduction (P < 0.001).”
Humanscombined with atorvastatin compared to atorvastatin alone6 monthsn = 34
PeerJ
Resistance training
downin humans4
4 studies
Resistance training
downin humans4
Resistance training decreases LDL-C in all conditions (resistance training and concurrent training across protein intakes).
“Triglycerides, total cholesterol, LDL-C, and apolipoprotein B decreased and HDL-C increased in all conditions.”
Human trialin all conditions (resistance training and concurrent training across protein intakes)12 weeksfemales
European journal of nutrition
Resistance training decreases LDL-C in both training groups when compared to the control group.
“Significant time × group interaction (p < 0.05) revealed RT effects in both training groups for fat mass, trunk fat, glucose, LDL-c, IL-10, TNF-α, C-reactive protein, FOX, and AOPP when compared to the control group.”
Human trialin both training groups when compared to the control group12 weeksfemalesn = 54
International journal of environmental research and public health
Resistance training decreases LDL-C in humans (obese older women) (TG=85.1±11.0mg/dL vs. CG=148.7±0.1mg/dL, P<0.05).
“low-density lipoprotein (TG=85.1±11.0mg/dL vs. CG=148.7±0.1mg/dL)”
Human trialobese older women8weeksfemalesn = 38
Experimental gerontology
Resistance training decreases LDL-C in humans (adults with overweight or obesity) (MD = -0.25 mmol/L; 95% CI: -0.41 to -0.08).
“RT significantly reduced diastolic blood pressure (MD = -1.53 mmHg; 95% CI: -2.16 to -0.91; p < 0.01), LDL-C (MD = -0.25 mmol/L; 95% CI: -0.41 to -0.08; p < 0.01)”
Reviewadults with overweight or obesity2-3 sessions/week≥ 7 weeksn = 454
Obesity reviews : an official journal of the International Association for the Study of Obesity
Curcumin
downin humans3no changein humans1
4 studies
Curcumin
downin humans3no changein humans1
Curcumin decreases LDL-C in humans (compared with placebo, added to glimepiride).
“Compared to placebo, significant decreases were observed in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C)”
Human trialcompared with placebo, added to glimepiride1100 mg once dailythree months
BMC pharmacology & toxicology
Curcumin decreases LDL-C in humans (added to metformin compared with metformin alone) (117.9 ± 24 vs 91.12 ± 19.46 mg/dL (metformin alone vs curcumin plus metformin)).
“Post-treatment LDL-C levels in groups 1 and 2 were 117.9 ± 24 and 91.12 ± 19.46 mg/dL, respectively (p < 0.01).”
Human trialadded to metformin compared with metformin alonenanomicelle80 mg/day3 monthsfemalesn = 100
Advances in experimental medicine and biology
Curcumin showed no clear effect on LDL-C in humans (mild COPD).
“The percent changes in blood pressure and hemoglobin A1c and LDL-cholesterol, triglyceride, or high-density lipoprotein-cholesterol levels after treatment were similar for the two groups.”
Human trialmild COPDTheracurmin(®)24 weeksn = 39
International journal of chronic obstructive pulmonary disease
Curcumin decreases LDL-C in humans (compared to control group) (SMD = -0.340, 95% CI: -0.530 to -0.150, P < 0.0001).
“Turmeric and curcumin significantly reduced serum LDL-C (SMD = -0.340, 95% confidence interval [CI]: -0.530 to -0.150, P < 0.0001)”
Reviewcompared to control groupn = 649
Nutrition journal
Ezetimibe + atorvastatin
downin humans3
3 studies
Ezetimibe + atorvastatin
downin humans3
Ezetimibe + atorvastatin decreases LDL-C in humans (versus atorvastatin monotherapy) (MD -13.94%, 95% CI -18.90% to -9.10% vs atorvastatin alone).
“AS/EZ FDC reduced LDL-C more than AS alone (MD -13.94%, 95% CI [-18.90% to -9.10%])”
Human trialversus atorvastatin monotherapyfixed-dose combination
PeerJ
Ezetimibe + atorvastatin decreases LDL-C in humans (compared with atorvastatin alone) (LDL-C reduction 45.15% vs 29.43% with atorvastatin alone at 4 weeks).
“29.43% in group A vs 45.15% in group B at 4 weeks (p < 0.001)”
Human trialcompared with atorvastatin aloneatorvastatin 80 mg plus ezetimibe 10 mg once daily4 weeks
The Journal of the Association of Physicians of India
Ezetimibe + atorvastatin decreases LDL-C in humans (Very high-risk ASCVD; compared with atorvastatin 40 mg monotherapy) (Week 6 LSMD: -21.2; P < 0.0001; week 12 LSMD: -16.0; P < 0.0001).
“The EZ/AS lipid-lowering effect was statistically greater than AS monotherapy at week 6 (LSMD: -21.2; P < 0.0001) and week 12 (LSMD: -16.0; P < 0.0001).”
Human trialVery high-risk ASCVD; compared with atorvastatin 40 mg monotherapyezetimibe 10 mg + atorvastatin 40 mg once daily6 weeksn = 137
BMC cardiovascular disorders
Bempedoic acid + ezetimibe
downin humans2downin reviews1−36% reduction
3 studies
Bempedoic acid + ezetimibe
downin humans2downin reviews1−36% reduction
Bempedoic acid + ezetimibe decreases LDL-C in humans (-36.90% percent change (95% CI -44.65 to -29.15)).
“followed by bempedoic acid plus ezetimibe (-36.90%; 95% CI: -44.65 to -29.15)”
Human trial
Endocrinology, diabetes & metabolism
Bempedoic acid + ezetimibe is linked with lower LDL-C in humans (33%, p < 0.0001).
“By 3 months, BA (21%) and BA + EZE (33%, p < 0.0001 for both) were associated with significant reductions in median LDL-C levels.”
Humans3 monthsn = 615
LDL-C lowering in patients treated with bempedoic acid in a real-world cohort
Atherosclerosis plus
Bempedoic acid + ezetimibe decreases LDL-C in high-risk patients (approximately 36.2% reduction).
“the fixed-dose combination of bempedoic acid and ezetimibe produces an approximately 36.2% reduction in LDL-C in high-risk patients”
Reviewin high-risk patientsfixed-dose combination
Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets
Frontiers in medicine
Laroprovstat
downin humans2downin silico1−51% reduction
3 studies
Laroprovstat
downin humans2downin silico1−51% reduction
Laroprovstat decreases LDL-C in humans after 3-week rosuvastatin 20 mg run-in (51% (95% CI: 58, 44)).
“laroprovstat 1 mg and 30 mg reduced LDL-C by 29% (95% CI: 38, 18) and 51% (95% CI: 58, 44)”
Human trialafter 3-week rosuvastatin 20 mg run-in30 mg once daily28 days
AHA Scientific Sessions 2025 abstract
Laroprovstat decreases LDL-C in humans (dose-dependent) (up to 51% reduction).
“produced dose-dependent LDL-C reductions of up to 51% in a phase 2 trial”
Reviewdose-dependent
Oral PCSK9 inhibitors: closing the gap between potency and practicality
Current opinion in lipidology
Laroprovstat decreases LDL-C in silico (added on top of rosuvastatin; simulated by integrated K-PD model) (additional reduction of approximately 50%).
“laroprovstat 30 mg, when added on top of rosuvastatin, produced an additional clinically meaningful LDL-C reduction of approximately 50%”
In silicoadded on top of rosuvastatin; simulated by integrated K-PD model30 mg
AHA Scientific Sessions 2025 abstract
Lipid-lowering therapy
downin humans3−70% decrease
3 studies
Lipid-lowering therapy
downin humans3−70% decrease
Lipid-lowering therapy decreases LDL-C in humans after lipid-lowering therapy (70% decrease).
“LDL-C decreased by 70% in both T2D and controls”
Human trialafter lipid-lowering therapy1 month
AHA Scientific Sessions 2025 abstract
Lipid-lowering therapy is linked with lower LDL-C in genetically confirmed FH (from 267 ± 82 mg/dL at baseline to 100 ± 57 mg/dL at last follow-up).
“In genetically confirmed FH, mean LDL-cholesterol decreased from 267 ± 82 mg/dL at baseline to 100 ± 57 mg/dL at last follow-up”
Humansin genetically confirmed FHn = 91
Acta clinica Belgica
Lipid-lowering therapy is linked with lower LDL-C in humans (at 6 months in post-ACS patients after PCI) (≥50% reduction in 24/82 (29.3%) without reaching <55 mg/dL).
“A ≥ 50% LDL-C reduction without meeting the < 55 mg/dL threshold was observed in 24/82 patients (29.3%).”
Humansat 6 months in post-ACS patients after PCI6 monthsn = 82
Lipid-Lowering Therapy in Post-Acute Coronary Syndrome Patients: An Observational Study
Cardiology research
Atorvastatin
downin humans3−80% decrease
3 studies
Atorvastatin
downin humans3−80% decrease
Atorvastatin decreases LDL-C in humans (on background PCSK9 inhibitor therapy) (80% decrease).
“After 1 month of LLT, LDL-C and hsCRP decreased by 80% and 6%, respectively, in the statin group (P<0.05 for each).”
Human trialon background PCSK9 inhibitor therapy80 mg1 month
AHA Scientific Sessions 2025 abstract
Atorvastatin decreases LDL-C in humans (-40 mg/dL).
“Atorvastatin treatment reduced LDL-c by 40 mg/dL (β = −40.045; CI95% = −69.949–−10.140; p = 0.010).”
Human trial60-dayfemalesn = 39
Antioxidants (Basel, Switzerland)
Atorvastatin is linked with lower LDL-C in humans (dyslipidemia) (-54.55%).
“In 55 patients who completed follow-up, a decrease in LDL-C, total cholesterol, triglycerides, and ApoE was 54.55%, 40.60%, 53.1%, and 40.46%, respectively.”
Humansdyslipidemia12-weekn = 55
Research SquarePreprint
Lipid-lowering medication
downin humans2
2 studies
Lipid-lowering medication
downin humans2
Lipid-lowering medication decreases LDL-C in Group 3.
“There was a linear trend in changes in LDL-C levels from baseline to 36 months; the largest decrease being −0.76 in Group 3 (−0.90 to − 0.62, p =.001, adjusted for baseline value) as seen in.”
Human trialin Group 336 months
Scandinavian journal of primary health care
Lipid-lowering medication decreases LDL-C in humans (Group 3 baseline LDL-C > 2.6 mmol/L) (-0.76 mmol/L (-21%)).
“During the 36-month follow-up, the mean LDL-C values decreased statistically significantly in group 3 (-0.76 mmol/L, 95% CI -0.90 to -0.62, -21%, p < .001: [ANCOVA]).”
Human trialGroup 3 baseline LDL-C > 2.6 mmol/L36-monthn = 507
Scandinavian journal of primary health care
Lipid-lowering medication is linked with lower LDL-C in both users and nonusers over follow-up.
“Total cholesterol, LDL-C, and triglycerides decreased for users and nonusers (p < .0001).”
Humansin both users and nonusers over follow-uptwelve years of follow-upmalesn = 63,357
Preventive medicine
All 127Fewer
Effects
16Major adverse cardiovascular events
no changein humans1HR 1.02
1 study
Major adverse cardiovascular events
no changein humans1HR 1.02
LDL-C was not clearly linked with major adverse cardiovascular events in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 1.02, 95% CI 0.99-1.05; p=0.19).
“MACE risk was similar between groups (HR 1.02, 95% CI 0.99-1.05, p=0.19).”
HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens
Very low “bad” cholesterol not linked to added cognitive risk
AHA Scientific Sessions 2026 abstract
Hemorrhagic stroke
no changein humans1HR 1
1 study
Hemorrhagic stroke
no changein humans1HR 1
LDL-C was not clearly linked with hemorrhagic stroke in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 1.00, 95% CI 0.96-1.04; p=0.91).
“No significant difference was observed in hemorrhagic stroke risk (HR 1.00, 95% CI 0.96-1.04, p=0.91).”
HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens
Very low “bad” cholesterol not linked to added cognitive risk
AHA Scientific Sessions 2026 abstract
Vascular dementia
no changein humans1HR 0.96
1 study
Vascular dementia
no changein humans1HR 0.96
LDL-C was not clearly linked with vascular dementia in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 0.96, 95% CI 0.92-1.00; p=0.60).
“No significant increase was observed for vascular dementia (HR 0.96, 95% CI 0.92-1.00, p=0.60).”
HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens
Very low “bad” cholesterol not linked to added cognitive risk
AHA Scientific Sessions 2026 abstract
Incident cognitive impairment
no changein humans1HR 1
1 study
Incident cognitive impairment
no changein humans1HR 1
LDL-C was not clearly linked with incident cognitive impairment in humans (Established ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dL) (HR 1.00, 95% CI 0.98-1.02; p=0.12).
“LDL-C <30 mg/dL was not associated with increased risk of incident cognitive impairment compared with LDL-C 30-55 mg/dL”
HumansEstablished ASCVD receiving lipid-lowering therapy; LDL-C <30 versus 30-55 mg/dLMedian approximately 3.1 years33.6% womens
Very low “bad” cholesterol not linked to added cognitive risk
AHA Scientific Sessions 2026 abstract
Elevated hs-CRP
no changein humans1OR 1.04
1 study
Elevated hs-CRP
no changein humans1OR 1.04
LDL-C was not clearly linked with elevated hs-CRP in humans (Statin users with prior ASCVD; LDL-C <70 versus 70-<100 mg/dL) (Adjusted OR 1.04, p=0.93).
“hs-CRP elevation was no different between adults with LDL-C <70 and 70-<100 mg/dL (adjusted OR 1.04, p=0.93)”
HumansStatin users with prior ASCVD; LDL-C <70 versus 70-<100 mg/dL
Residual Inflammatory Risk Among Statin-Treated US Adults with ASCVD Achieving LDL-C Control
AHA Scientific Sessions 2026 abstract
Major adverse cardiovascular events
no changein humans1HR 1.26
1 study
Major adverse cardiovascular events
no changein humans1HR 1.26
LDL-C was not clearly linked with major adverse cardiovascular events in humans (Acute coronary syndrome after percutaneous coronary intervention; per 1 mmol/L increase) (Adjusted HR 1.26 per 1 mmol/L increase; P=0.140).
“whereas absolute LDL-C level at 6 weeks (per 1 mmol/L increase) and attainment of LDL-C <1.4 mmol/L at 6 weeks were not”
HumansAcute coronary syndrome after percutaneous coronary intervention; per 1 mmol/L increase6 weeks after PCIn = 1,505
ESC Congress 2026 abstract
Cardiac events
downin humans1
1 study
Cardiac events
downin humans1
LDL-C decreases cardiac events in humans (to levels as low as 5 to 10 mg/dL).
“lowering plasma LDL-C to levels as low as 5 to 10 mg/dL is associated with further reduction in cardiac events”
Review
Cholesterol: Facts and Opinions by a Non-lipid Cardiologist
Methodist DeBakey cardiovascular journal
Phase angle at 50 kHz
no changein humans1
1 study
Phase angle at 50 kHz
no changein humans1
LDL-C was not clearly linked with Phase angle at 50 kHz in humans after myocardial infarction (R=-0.004).
“LDL-C reduction was not correlated with change in PhA50 (R=-0.004; p = 0.981)”
Humansafter myocardial infarction55 daysn = 45
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
Coronary plaque progression
no changein humans1
1 study
Coronary plaque progression
no changein humans1
LDL-C showed no clear effect on coronary plaque progression in lean mass hyper-responders.
“neither ApoB levels nor cumulative LDL-C exposure predicted plaque progression in this population of LMHR and near-LMHR individuals”
Human trialin lean mass hyper-respondersone yearn = 100
medRxivPreprint
Blood pressure control
downin humans1
1 study
Blood pressure control
downin humans1
LDL-C is linked with worse blood pressure control in humans (hypertensive older adults).
“LDL-C, the A allele of the REN gene (G2646A), and genotype II of the ACE gene (InDel) were significantly associated with inadequate BPC”
Humanshypertensive older adultsn = 143
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
All 16Fewer
Upstream
11Calendar year
no changein humans1
1 study
Calendar year
no changein humans1
calendar year was not clearly linked with LDL-C in humans (Admission for AMI) (123 mg/dL in 2005 vs 128 mg/dL in 2022).
“Admission LDL-C levels remained stable over time (123 mg/dL in 2005 vs 128 mg/dL in 2022).”
HumansAdmission for AMI2005–2022
ESC Congress 2026 abstract
Menopause transition
upin humans1
1 study
Menopause transition
upin humans1
Menopause transition increases LDL-C in humans (declining estrogen levels during menopause transition).
“As estrogen levels decline, women experience significant increases in low-density lipoprotein cholesterol (LDL-C) and triglycerides”
Reviewdeclining estrogen levels during menopause transitionfemales
Maturitas
PCSK9
downin mice1−54%
1 study
PCSK9
downin mice1−54%
PCSK9 decreases LDL-C in mice (AD-transgenic mice) (-54%).
“PCSK9 knockout reduced low-density lipoprotein-cholesterol by 54%”
AnimalsAD-transgenic mice
PCSK9 Inhibitors Do Not Increase Cognitive Risk
Research SquarePreprint
Estradiol
downin humans1
1 study
Estradiol
downin humans1
Estradiol is linked with lower LDL-C in humans (oral estrogen; large increase in estradiol during HRT).
“In women receiving oral estrogen, LDL-C was significantly decreased and TG was significantly increased in the group with a large increase in estradiol.”
Humansoral estrogen; large increase in estradiol during HRToralfemalesn = 117
The journal of medical investigation : JMI
Frailty index
downin humans1OR 0.87
1 study
Frailty index
downin humans1OR 0.87
Frailty index is linked with lower LDL-C in humans (OR = 0.87, 95% CI 0.78-0.97).
“negatively associated with the risk of LDL-C (OR = 0.87, 95% CI 0.78-0.97)”
Humans
Frailty and risk of systemic atherosclerosis: A bidirectional Mendelian randomization study
PloS one
Older age
downin humans1
1 study
Older age
downin humans1
Older age is linked with lower LDL-C in humans (heterozygous FH) (125 vs. 146 mg/dL (p < 0.05)).
“post-treatment LDL-C levels were lower in elderly than younger patients (125 vs. 146 mg/dL, p < 0.05)”
Humansheterozygous FHn = 2,273
Biomedicines
TNF-alpha
mediatesin humans1
1 study
TNF-alpha
mediatesin humans1
TNF-alpha is linked with LDL-C in humans (partial mediation of the cobalt association, together with 8-iso-PGF2α).
“The elevation of TNF-α and 8-iso-PGF2α partially mediated Co-caused elevation of TC and LDL-C.”
Humanspartial mediation of the cobalt association, together with 8-iso-PGF2αn = 420
Environmental science and pollution research international
MT-ND2
downin humans1
1 study
MT-ND2
downin humans1
MT-ND2 is linked with lower LDL-C in Japanese populations (SMD = -0.11, 95% CI = -0.22 to 0.00).
“However, the association of m.5178C>A variant with lower low-density lipoprotein cholesterol (LDL-C) levels were only observed in Japanese populations (SMD = -0.11, 95% CI = -0.22 to 0.00, P=0.04).”
Humansin Japanese populations
Association of m.5178C>A variant with serum lipid levels: a systematic review and meta-analysis
Bioscience reports
APOE ε2 allele
downin humans1
1 study
APOE ε2 allele
downin humans1
APOE ε2 allele is linked with lower LDL-C in humans (carriers versus noncarriers).
“The serum LDL-C and ApoB of the ε2 carriers were lower than the noncarriers in the middle-aged and elderly males (all P < 0.05).”
Humanscarriers versus noncarriersmales
Lipids in health and disease
Age
upin humans1
1 study
Age
upin humans1
age is linked with higher LDL-C in humans (+64%, median +54 mg/dL).
“From 20 till 49 years of age, men were found to exhibit a steep 64% increase of LDL-C (median +54 mg/dL), while triglyceride levels increased almost two-fold.”
Humansmales
Journal of clinical lipidology
All 11Fewer
Associations
84Mortality
upin humans4downin humans3HR 1.07–2.54
7 studies
Mortality
upin humans4downin humans3HR 1.07–2.54
LDL-C is associated with mortality in humans (Type 2 diabetes and chronic kidney disease; sustained LDL-C 3.4 versus 1.8 mmol/l) (HR 1.40 (1.10–1.74), sustained LDL-C 3.4 versus 1.8 mmol/l).
“sustained LDL-C 3.4 versus 1.8 mmol/l had a hazard ratio of 1.40 (1.10–1.74).”
HumansType 2 diabetes and chronic kidney disease; sustained LDL-C 3.4 versus 1.8 mmol/lMedian follow-up 5.04 yearsn = 7,978
Diabetes therapy : research, treatment and education of diabetes and related disorders
LDL-C is associated with mortality in patients with ASCVD (aHR= 0.60 [0.54, 0.65]).
“When compared to LDL-C level of 70–<100 mg/dL, LDL-C of <55 mg/dL and 55-<70 mg/dL were associated with lower mortality risk (aHR= 0.60 [0.54, 0.65] for <55 mg/dL”
Humansin patients with ASCVD
ESC Congress 2026 abstract
LDL-C is associated with mortality in statin-treated ESKD hemodialysis patients, restricted cubic spline analysis.
“Restricted cubic spline analyses demonstrated an association between lower LDL-C levels and reduced risks of both all-cause mortality and cardiovascular death.”
Humansin statin-treated ESKD hemodialysis patients, restricted cubic spline analysisn = 3,431
Atherosclerosis
LDL-C is linked with a higher risk of mortality in humans (diabetes not at high cardiovascular risk) (HR = 2.27; 95%CI 1.51-3.41).
“participants with LDL-C values < 100 mg/dL and <70 mg/dL had greater adjusted mortality compared to those with LDL-C 100-129 mg/dL (HR = 1.67; 95%CI 1.21-2.30 and HR = 2.27; 95%CI 1.51-3.41, respectively).”
Humansdiabetes not at high cardiovascular risk<70 mg/dL10.3 yearsn = 2,098
Journal of clinical medicine
LDL-C is linked with a higher risk of mortality in humans (HR: 1.07, 95% CI: 1.02,1.12).
“all-cause and CVD mortality risks for participants in the fourth quartile compared with participants in the third quartile for LDL-C of (HR: 1.07, 95% CI: 1.02,1.12)”
Humansn = 69,068
Frontiers in endocrinology
LDL-C is linked with a lower risk of mortality in statin users.
“In statin users, lower LDL-C was associated with a decreased hazard of mortality during follow-up.”
Humansin statin users
Diabetes & metabolism journal
LDL-C predicts mortality in humans (compared with LDL-C >= 144 mg/dL) (HR 2.54, 95% CI 1.58-4.07).
“the multivariable-adjusted Hazard ratio (and 95% confidence interval) for all-cause mortality was 2.54 (1.58-4.07) for those with LDL-C levels below 70 mg/dL”
Humanscompared with LDL-C >= 144 mg/dL7 or 10 yearsn = 3,684
Lipids in health and disease
Atherosclerotic cardiovascular disease
upin humans3downin humans1
4 studies
Atherosclerotic cardiovascular disease
upin humans3downin humans1
LDL-C is linked with a higher risk of atherosclerotic cardiovascular disease in humans (sHR 1.69, 95% CI 1.35-2.12).
“Elevated LDL-C by all equations was associated with ASCVD events (subdistribution hazards ratio [95% CI]: Martin-Hopkins, 1.69 [1.35-2.12]”
Humans22.7 yearsn = 10,550
Martin-Hopkins LDL equation best predicts cardiovascular risk
Circulation. Population health and outcomes
LDL-C raises the risk of atherosclerotic cardiovascular disease in humans.
“elevated low-density lipoprotein cholesterol (LDL-C) recognized as a causal factor and the primary target for the prevention of atherosclerotic cardiovascular disease (ASCVD)”
Review
Are we underestimating the benefits of lipid-lowering therapies?
Pharmacological reviews
LDL-C lowers the risk of atherosclerotic cardiovascular disease in randomised clinical trials.
“Evidence from randomised clinical trials confirms that incremental LDL-C reductions lead to proportional reductions in cardiovascular events”
Reviewin randomised clinical trials
Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice
Current atherosclerosis reports
LDL-C raises the risk of atherosclerotic cardiovascular disease in humans.
“Even younger individuals with a greater cumulative exposure to LDL-C, despite their age, may have a higher overall risk compared to older individuals with a lower cumulative exposure to LDL-C.”
Review
American journal of preventive cardiology
Cardiovascular disease
downin humans2HR 0.71
2 studies
Cardiovascular disease
downin humans2HR 0.71
LDL-C is linked with a lower risk of cardiovascular disease in humans (HR 0.71; 95% [CI], 0.53-0.95).
“patients with LDL-C <55 mg/dL had a significantly lower risk of cardiovascular death compared with LDL-C ≥100 mg/dL (HR 0.71; 95% [CI], 0.53-0.95)”
Humansin ESKD patients receiving maintenance hemodialysis and statin therapy, LDL-C <55 mg/dL vs ≥100 mg/dLn = 3,431
Atherosclerosis
LDL-C lowers the risk of cardiovascular disease in high-risk primary prevention.
“reducing LDL-C to lower levels than those recommended in current guidelines”
Reviewin high-risk primary prevention
Journal of clinical lipidology
APOE
upin humans1downin humans1
2 studies
APOE
upin humans1downin humans1
APOE is associated with LDL-C in humans (dyslipidemic patients on atorvastatin) (p= 0.05).
“Reduction in LDL-C levels was associated with variants of rs429358(T>C) [p= 0.05]”
Humansdyslipidemic patients on atorvastatin
Research SquarePreprint
APOE is associated with LDL-C in humans (E2 vs. E3) (MD -5.58, 95% CI -8.04 to -2.51).
“APOE (E2 vs. E3, mean difference = -5.58, 95% CI: -8.04 to -2.51, P < 0.00001]”
ReviewE2 vs. E3n = 6,167
Pharmacogenetics and genomics
Myocardial infarction
upin humans1downin humans1
2 studies
Myocardial infarction
upin humans1downin humans1
LDL-C is linked with a higher risk of myocardial infarction in humans (somatic statin-naive individuals) (aHR 1.57 (95% CI: 1.06-2.32) per 1 mmol/L).
“At age 76-92 and 61-75 years, the aHRs for MI were 1.57 (1.06-2.32) and 1.22 (1.03-1.44) per 1 mmol/L higher LDL-C.”
Humanssomatic statin-naive individuals
European journal of preventive cardiology
LDL-C is linked with a lower risk of myocardial infarction in humans.
“A decrease in LDL-C was associated with lower hazards of MI and stroke.”
Humans
Diabetes & metabolism journal
ApoB/ApoA-I ratio
mixedin humans1upin humans1
1 study
ApoB/ApoA-I ratio
mixedin humans1upin humans1
LDL-C predicts ApoB/ApoA-I ratio in humans (multivariate regression in adults with normal lipid profiles).
“Multivariate regression identified LDL-C and LDL/ApoB ratio as independent predictors of the ApoB/ApoA-I ratio.”
Humansmultivariate regression in adults with normal lipid profilesserumn = 104
Lipids
ApoB/ApoA-I ratio is associated with LDL-C in humans (normal lipid profiles; ApoB/ApoA-I ratio > 0.8).
“Participants with an ApoB/ApoA-I ratio > 0.8 showed significantly higher total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-HDL-C, triglycerides, and atherogenic indices”
Humansnormal lipid profiles; ApoB/ApoA-I ratio > 0.8serumn = 104
Lipids
All-cause dementia
upin humans1mixedin humans1
1 study
All-cause dementia
upin humans1mixedin humans1
LDL-C is linked with a higher risk of all-cause dementia in humans (statin users, with or without diabetes).
“Rather, an advance in LDL-C levels was associated with an increase in the hazard of all-cause dementia in statin users, regardless of the presence of diabetes.”
Humansstatin users, with or without diabetes
Scientific reports
LDL-C is associated with all-cause dementia in humans (statin non-users, with or without diabetes).
“In statin non-users with or without diabetes, the hazards of all-cause dementia were highest for those in the lowest quartile or quintile of low-density lipoprotein-cholesterol (LDL-C) level, showing an inverted J-shaped relationship.”
Humansstatin non-users, with or without diabetes
Scientific reports
Inclisiran
downin humans1
1 study
Inclisiran
downin humans1
Inclisiran is associated with LDL-C in humans (Median LDL-C reduction of 77% at day 14; baseline 138 mg/dL and day 14 31 mg/dL).
“Baseline LDL-C was 138 mg/dL and fell to 75 and 31 mg/dL at days 3 and 14 after the dose (median reductions 45% and 77%).”
HumansIschemic stroke; combined with intensified oral therapy, whose contribution cannot be isolated284 mg14 daysn = 15
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Physician-pharmacist protocol-based pharmacotherapy management
downin humans1
1 study
Physician-pharmacist protocol-based pharmacotherapy management
downin humans1
Physician-pharmacist protocol-based pharmacotherapy management is associated with LDL-C in humans After acute myocardial infarction; compared with physician-led care (49.0 versus 51.5 mg/dL; P = 0.074).
“Chronic-phase LDL-C was 49.0 versus 51.5 mg/dL (P = 0.074)”
HumansAfter acute myocardial infarction; compared with physician-led carechronic phase
Physician-Pharmacist PBPM for Intensive Lipid Management After Acute Myocardial Infarction
Journal of atherosclerosis and thrombosis
More on Physician-pharmacist protocol-based pharmacotherapy management
Coronary artery disease
upin humans1
1 study
Coronary artery disease
upin humans1
LDL-C is associated with coronary artery disease in humans (European ancestry without prior coronary heart disease).
“Higher levels of LDL-C, PRS CACS , and PRS SIS were independently associated with increased CHD risk (all P < 0.001).”
HumansEuropean ancestry without prior coronary heart diseaseMedian follow-up of 13.8 years45% malesn = 367,772
“Bad” cholesterol’s heart disease link grew with genetic risk
AHA Scientific Sessions 2026 abstract
Coronary plaque regression
downin humans1
1 study
Coronary plaque regression
downin humans1
LDL-C is associated with coronary plaque regression in humans (Statin-naive patients with stable coronary artery disease receiving lipid-lowering therapy).
“Lower achieved LDL-C levels were linearly associated with greater regression of TPV and NCPV.”
Human trialStatin-naive patients with stable coronary artery disease receiving lipid-lowering therapycoronary artery18 months82 male [79%]sn = 104
More intensive cholesterol therapy linked to less artery plaque
JAMA cardiology
Omega-3 fatty acids
downin humans1
1 study
Omega-3 fatty acids
downin humans1
Omega-3 fatty acids are associated with LDL-C in humans (pesco-vegetarian diet).
“the level of omega-3 fatty acid intake was correlated to the reduction of blood low-density lipoprotein cholesterol and total cholesterol.”
Human trialpesco-vegetarian dietblood1 week
Nutrition and health
APOB
upin humans1
1 study
APOB
upin humans1
APOB is associated with LDL-C in hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months (β = 0.758, P = .001).
“ANCOVA (adjusting for baseline) showed the TT genotype was independently associated with higher posttreatment LDL-C (β = 0.758; P = .001)”
Human trialin hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months3 monthsn = 79
Journal of cardiovascular pharmacology and therapeutics
Caloric restriction
mixedin humans1
1 study
Caloric restriction
mixedin humans1
Caloric restriction is associated with LDL-C in humans (between groups with different proportions of physical activity calories).
“Between the groups, the rate of change in serum LDL-C was significantly different.”
Human trialbetween groups with different proportions of physical activity calories4 weeks
Frontiers in physiology
HbA1c
upin humans1
1 study
HbA1c
upin humans1
LDL-C is associated with HbA1c in humans.
“In the total patient group, the HbA1c change (ΔHbA1c) was positively correlated with the LDL-C change (ΔLDL-C) and negatively correlated with baseline LDL-C.”
Human trial12 weeksn = 149
Frontiers in endocrinology
All 84Fewer
Funding
2 grants since 2026National Heart, Lung, and Blood Institute$463KEuropean Research Council€150K